Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 5 · 71.4%High 0 · 0%

Interferon vs glatiramer acetate

Relapse · patients with relapsing‐remitting multiple sclerosis

Interferons showed no clear difference in number of participants with relapse Risk ratio (M‐H, random, 95% CI) compared with glatiramer acetate (moderate certainty).

1 finding from 1 review

Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.04 [0.87, 1.24]
3 studies · 2184 participants
Moderate

Interferon vs glatiramer acetate

Number of participants with confirmed progression Risk ratio (M‐H, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis

Interferons showed no clear difference in number of participants with confirmed progression Risk ratio (M‐H,… compared with glatiramer acetate (moderate certainty).

1 finding from 1 review

Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.11 [0.91, 1.35]
3 studies · 2169 participants
Moderate

Interferon vs glatiramer acetate

Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis

Interferons showed no clear difference in number of participants who dropped out for AEs Risk ratio (M‐H,… compared with glatiramer acetate (low certainty).

1 finding from 1 review

Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 0.95 [0.64, 1.4]
4 studies · 2685 participants
Low

Interferon vs glatiramer acetate

Mean number of active T2 lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis

1 finding from 1 review

Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1790 participants
Low

Interferon vs glatiramer acetate

Mean number of new enhancing lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis

1 finding from 1 review

Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1734 participants
Moderate

Interferon vs glatiramer acetate

Mean change in total T2‐hyperintense lesion load Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis

1 finding from 1 review

Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1608 participants
Moderate

Interferon vs glatiramer acetate

Mean change in total T1‐hypointense lesion load · patients with relapsing‐remitting multiple sclerosis

1 finding from 1 review

Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1602 participants
Moderate